Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 80, Issue 2, 2011, Pages 437-444

  Sharma, Navesh K ^a   Li, Tianyu ^a   Chen, David Y ^a   Pollack, Alan ^b   Horwitz, Eric M ^a   Buyyounouski, Mark K ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Androgen deprivation therapy; Gastrointestinal toxicity; Intensity modulated radiotherapy; Prostate cancer

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; CONFIDENCE INTERVAL; GASTROINTESTINAL TOXICITIES; HAZARD RATIO; INTENSITY-MODULATED RADIOTHERAPY; INTERNATIONAL COMMISSION; KAPLAN-MEIER ESTIMATES; LATE EFFECTS; MEDIAN RADIATION; MULTI VARIATE ANALYSIS; NORMAL TISSUE; ODDS RATIOS; PLANNING TARGET VOLUMES; PROSTATE CANCER; PROSTATE CANCERS; RADIATION DOSE; RADIATION MORBIDITY; RADIATION UNIT; RECTAL TOXICITY; STANDARD DEVIATION; THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY (3D-CRT);

DISEASES; DOSIMETRY; MULTIVARIANT ANALYSIS; PATIENT MONITORING; PHYSICAL THERAPY; RADIATION EFFECTS; RADIOTHERAPY; STATISTICS; TISSUE; TOXICITY;

THREE DIMENSIONAL;

ANTIANDROGEN; GONADORELIN AGONIST;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION INJURY; SYMPTOM; TREATMENT OUTCOME; UROGENITAL TRACT INJURY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; FOLLOW-UP STUDIES; GASTROINTESTINAL TRACT; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; UROGENITAL SYSTEM;

EID: 79955596938     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.02.040     Document Type: Article

References (25)

1. A. Al-Mamgani, W.D. Heemsbergen, and S.T. Peeters Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 72 2008 980 988
2. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74 (Pubitemid 350251041)
3. A. Pollack, G.K. Zagars, and G. Starkschall Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial Int J Radiat Oncol Biol Phys 53 2002 1097 1105 (Pubitemid 34787842)
4. M.J. Zelefsky, S.A. Leibel, and P.B. Gaudin Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer Int J Radiat Oncol Biol Phys 41 1998 491 500 (Pubitemid 28275076)
5. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial Lancet 360 2002 103 106
6. G.E. Hanks, T.F. Pajak, and A. Porter Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group protocol 92-02 J Clin Oncol 21 2003 3972 3978 (Pubitemid 46606211)
7. E.M. Horwitz, K. Bae, and G.E. Hanks Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504
8. M.V. Pilepich, K. Winter, and M.J. John Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252 (Pubitemid 32727802)
9. S.J. Feigenberg, A.L. Hanlon, and E.M. Horwitz Long-term androgen deprivation increases grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy Int J Radiat Oncol Biol Phys 62 2005 397 405 (Pubitemid 40704456)
10. C.A. Lawton, K. Bae, and M. Pilepich Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of Radiation Therapy Oncology Group studies 85-31, 86-10, and 92-02 Int J Radiat Oncol Biol Phys 70 2008 437 441
11. C.A. Lawton, M. DeSilvio, and M. Roach III An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions Int J Radiat Oncol Biol Phys 69 2007 646 655 (Pubitemid 47418390)
12. L. Dong, J. Antolak, and M. Salehpour Patient-specific point dose measurement for IMRT monitor unit verification Int J Radiat Oncol Biol Phys 56 2003 867 877 (Pubitemid 36677384)
13. M.J. Zelefsky, H. Chan, and M. Hunt Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer J Urol 176 2006 1415 1419 (Pubitemid 44307191)
14. A. Al-Mamgani, W.D. Heemsbergen, and S.T. Peeters Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer Int J Radiat Oncol Biol Phys 73 2009 685 691
15. E.M. Horwitz, A.L. Hanlon, and W.H. Pinover Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques Cancer 92 2001 1281 1287
16. R.A. Price, S. Murphy, and S.W. McNeeley A method for increased dose conformity and segment reduction for SMLC delivered IMRT treatment of the prostate Int J Radiat Oncol Biol Phys 57 2003 843 852 (Pubitemid 37194313)
17. A.F. Monti, A. Ostinelli, and M. Frigerio An ICRU 50 radiotherapy treatment chart Radiother Oncol 35 1995 145 150
18. R. Jacob, A.L. Hanlon, and E.M. Horwitz Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement Int J Radiat Oncol Biol Phys 61 2005 695 701 (Pubitemid 40247963)
19. A. Pollack, A.L. Hanlon, and E.M. Horwitz Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial Int J Radiat Oncol Biol Phys 64 2006 518 526 (Pubitemid 43083441)
20. M.K. Buyyounouski, A.L. Hanlon, and E.M. Horwitz Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy Int J Radiat Oncol Biol Phys 70 2008 59 66 (Pubitemid 350251025)
21. M. Roach III, M. DeSilvio, and C. Lawton Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413 J Clin Oncol 21 2003 1904 1911 (Pubitemid 46606377)
22. G. Sanguineti, M. Marcenaro, and P. Franzone Neoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapy Radiother Oncol 66 2003 151 157 (Pubitemid 36315824)
23. T.E. Schultheiss, W.R. Lee, and M.A. Hunt Late GI and GU complications in the treatment of prostate cancer Int J Radiat Oncol Biol Phys 37 1997 3 11 (Pubitemid 27090129)
24. P. Alcantara, T.E. Schultheiss, and K. Ruth Dose-volume determinants of late genitourinary toxicity after external beam radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 63 2005 S294
25. M.J. Zelefsky, E.J. Levin, and M. Hunt Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 70 2008 1124 1129 (Pubitemid 351296130)